Replies to post #135778 on Innovation Pharmaceuticals Inc (IPIX)

[Ernesto]

A partnership implies third-party validation

True, but at what cost. Third-party validation is for short term gains.

A partnership reduces future dilution.

All depends on how much you get paid and what percentage you give up relative to selling shares to fund the trials. CTIX isn't bringing drugs to market but they may bring some to approval. If the stock price straightens out and moves up to $10 I wouldn't be surprised if we take B, B-OM and P all through phase 3 since they will be short and cheap with the pathways available.

Due to Kevetrin's massive and broad potential I expect we'll have numerous partnerships there and hope we get one shortly on at least one indication. Again though, if we can fund it with minimal sales and grants, etc. it may just be better to do that.